---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-152145"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2026-04-13T23:59:59+00:00"
generated_at: "2026-05-15T06:36:06.838556+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma triggers $250M milestone after positive daraxonrasib Phase 3 results

## Summary
- Revolution Medicines' RASolute 302 trial met primary and key secondary endpoints (PFS and OS) in metastatic PDAC.
- Royalty Pharma funded $250M upfront; positive data triggers additional $250M milestone, total $500M funded.
- Royalty Pharma now earns 4.55% tiered royalty on daraxonrasib sales up to $2B, lower rates above $2B.
- Additional $750M synthetic royalty available upon FDA approval and other milestones; first $250M on approval.
- Senior secured loan of up to $750M available; first $250M tranche must be drawn after FDA approval.

## SEC filing metadata
- accession: 0001193125-26-152145
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2026-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312526152145/0001193125-26-152145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312526152145/d871473d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-152145
- JSON: https://secwatch.observer/filing/0001193125-26-152145.json
- Plain text: https://secwatch.observer/filing/0001193125-26-152145.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.